CRSP today
$44.76-$0.99 (-2.16%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minBearish
5 minExpanding
Daily trend turns down below $46.92
Key levels
Resistance$51.52
Resistance$47.76
Support$44.12
Support$39.81
Latest news & SEC filings
ProductCRISPR Therapeutics Reports Lower Blood Fat Levels From Experimental Gene-Editing Treatment
ProductCRISPR Therapeutics reports positive Phase 1b data for CTX310
All CRSP news →About CRISPR Therapeutics
CRISPR Therapeutics is a biopharmaceutical company that develops gene-based medicines using CRISPR/Cas9 gene editing technology. Its programs cover hemoglobinopathies, in vivo liver editing, CAR T cell therapies, and regenerative medicine, including CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, developed with Vertex Pharmaceuticals. The company also works on siRNA-based treatments and stem cell-derived therapies for Type 1 diabetes, operating in the United States, Europe, and other regions.
Based on the company's 10-K filed Feb 12, 2026.
Nasdaq · Healthcare
CRISPR Therapeutics AG (CRSP)
What Is the Price Target for CRSP?
SEPT Low Target
$68.00
SEPT Mid Target
$80.00
SEPT High Target
$92.00
Analyst Consensus
$80.00
Is CRSP a Buy or Sell Right Now?
Thesis
- •Revenue growing -90.6% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRSP.
Start Free Trial →Is CRSP Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$80.00
25
Moat Score
NONE
1/9
Piotroski Score
7.3
Altman Z-Score
What Is Smart Money Doing with CRSP?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kulkarni Samarth | director officer | Sale | 47,837 | $2.4M | Oct 19, 2026 |
| Kulkarni Samarth | director officer | Buy | 100,000 | - | Oct 16, 2026 |
| KASINGER JAMES R. | officer | Sale | 1,040 | $51K | Oct 14, 2026 |
| Kulkarni Samarth | director officer | Sale | 4,098 | $202K | Oct 14, 2026 |
| George Simeon | director | Buy | 30,000 | $420K | Oct 14, 2026 |
| George Simeon | director | Sale | 14,514 | $720K | Oct 14, 2026 |
| KASINGER JAMES R. | officer | Buy | 2,113 | - | Oct 13, 2026 |
| Kulkarni Samarth | director officer | Buy | 8,333 | - | Oct 13, 2026 |
| KASINGER JAMES R. | officer | Buy | 1,990 | $27K | Oct 6, 2026 |
| KASINGER JAMES R. | officer | Sale | 1,990 | $119K | Oct 6, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CRSP Growth Story
Revenue YoY
-90.6%
3yr Revenue CAGR
43.1%
EPS Growth YoY
-49.08%
FCF Growth YoY
-139.1%
Revenue Trend
STRONG
Dark Pool Trades for CRSP
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CRSP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:30:04 | $44.50 | 1,166 | $$52K | SELL |
| 14:08:36 | $44.85 | 2,100 | $$94K | SELL |
| 22:38:04 | $45.80 | 1,100 | $$50K | SELL |
| 22:12:06 | $45.91 | 2,000 | $$92K | SELL |
| 21:30:45 | $46.00 | 7,113 | $$327K | SELL |
5 dark pool trades shown · $$615K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CRISPR Therapeutics AG (CRSP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CRSP — frequently asked questions
What is CRSP stock price today?
CRISPR Therapeutics AG (CRSP) is at $44.76, down 2.16% (-$0.99) at the Nov 12, 2026 close.
Why is CRSP stock moving today?
Latest CRSP news — Nov 10, 2026: CRISPR Therapeutics Reports Lower Blood Fat Levels From Experimental Gene-Editing Treatment · Nov 9, 2026: CRISPR Therapeutics reports positive Phase 1b data for CTX310
What is the CRSP price target?
The average analyst price target for CRSP is $80.00, ranging from $52 to $88, based on 5 analysts. Latest: UBS initiates on Oct 15, 2026.
What do analysts rate CRSP?
Analyst ratings for CRSP: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did CRSP beat earnings?
CRSP last reported on Aug 3, 2026: EPS -$0.94 vs -$1.19 expected — a beat of 21.0%.
Does CRSP pay a dividend?
CRSP does not currently pay a dividend.
How much debt does CRSP have?
CRISPR Therapeutics AG reported $586M of debt and $291M of cash (Jun 30, 2026).
What are CRSP support and resistance levels?
Support: $44.12, $39.81, $35.38. Resistance: $47.76, $51.52, $55.82.
What are insiders doing with CRSP?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.
What is the latest news on CRSP?
Nov 10, 2026: CRISPR Therapeutics Reports Lower Blood Fat Levels From Experimental Gene-Editing Treatment · Nov 9, 2026: CRISPR Therapeutics reports positive Phase 1b data for CTX310